|
1
|
Lettre G, Palmer CD, Young T, Ejebe KG,
Allayee H, Benjamin EJ, Bennett F, Bowden DW, Chakravarti A,
Dreisbach A, et al: Genome-wide association study of coronary heart
disease and its risk factors in 8,090 African Americans: The NHLBI
CARe Project. PLoS Genet. 7:e10013002011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katzmarzyk PT, Perusse L, Rice T, Gagnon
J, Skinner JS, Wilmore JH, Leon AS, Rao DC and Bouchard C: Familial
resemblance for coronary heart disease risk: The HERITAGE family
study. Ethn Dis. 10:138–147. 2000.PubMed/NCBI
|
|
3
|
Loscalzo J and Handy DE: Epigenetic
modifications: Basic mechanisms and role in cardiovascular disease
(2013 Grover Conference series). Pulm Circ. 4:169–174. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhuang J, Peng W, Li H, Wang W, Wei Y, Li
W and Xu Y: Methylation of p15INK4b and expression of ANRIL on
chromosome 9p21 are associated with coronary artery disease. PLoS
One. 7:e471932012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baccarelli A, Rienstra M and Benjamin EJ:
Cardiovascular epigenetics: Basic concepts and results from animal
and human studies. Circ Cardiovasc Genet. 3:567–573. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Turunen MP, Aavik E and Ylä-Herttuala S:
Epigenetics and atherosclerosis. Biochim Biophys Acta.
1790:886–891. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feinberg AP: Phenotypic plasticity and the
epigenetics of human disease. Nature. 447:433–440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Friso S, Lotto V, Choi SW, Girelli D,
Pinotti M, Guarini P, Udali S, Pattini P, Pizzolo F, Martinelli N,
et al: Promoter methylation in coagulation F7 gene influences
plasma FVII concentrations and relates to coronary artery disease.
J Med Genet. 49:192–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guay SP, Brisson D, Munger J, Lamarche B,
Gaudet D and Bouchard L: ABCA1 gene promoter DNA methylation is
associated with HDL particle profile and coronary artery disease in
familial hypercholesterolemia. Epigenetics. 7:464–472. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dayeh TA, Olsson AH, Volkov P, Almgren P,
Ronn T and Ling C: Identification of CpG-SNPs associated with type
2 diabetes and differential DNA methylation in human pancreatic
islets. Diabetologia. 56:1036–1046. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang M, Sun JZ, Sun YL, You W, Dai J and
Li GS: Association between leptin gene promoter methylation and
type 2 diabetes mellitus. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.
29:474–477. 2012.(In Chinese). PubMed/NCBI
|
|
12
|
Samani NJ, Erdmann J, Hall AS,
Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund
P, Wichmann HE, et al: Genomewide association analysis of coronary
artery disease. N Eng J Med. 357:443–453. 2007. View Article : Google Scholar
|
|
13
|
Wellcome Trust Case Control Consortium, .
Genome-wide association study of 14,000 cases of seven common
diseases and 3,000 shared controls. Nature. 447:661–678. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pilbrow AP, Folkersen L, Pearson JF, Brown
CM, McNoe L, Wang NM, Sweet WE, Tang WH, Black MA, Troughton RW, et
al: The chromosome 9p21.3 coronary heart disease risk allele is
associated with altered gene expression in normal heart and
vascular tissues. PLoS One. 7:e395742012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soto JL, Cabrera CM, Serrano S and
López-Nevot MA: Mutation analysis of genes that control the G1/S
cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. BMC
Cancer. 5:362005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Eng J Med.
349:2042–2054. 2003. View Article : Google Scholar
|
|
17
|
Motterle A, Pu X, Wood H, Xiao Q, Gor S,
Ng FL, Chan K, Cross F, Shohreh B, Poston RN, et al: Functional
analyses of coronary artery disease associated variation on
chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet.
21:4021–4029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McPherson R, Pertsemlidis A, Kavaslar N,
Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA,
Tybjaerg-Hansen A, Folsom AR, et al: A common allele on chromosome
9 associated with coronary heart disease. Science. 316:1488–1491.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Helgadottir A, Thorleifsson G, Manolescu
A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A,
Sigurdsson A, Baker A, Palsson A, et al: A common variant on
chromosome 9p21 affects the risk of myocardial infarction. Science.
316:1491–1493. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jarinova O, Stewart AF, Roberts R, Wells
G, Lau P, Naing T, Buerki C, McLean BW, Cook RC, Parker JS and
McPherson R: Functional analysis of the chromosome 9p21.3 coronary
artery disease risk locus. Arterioscler Thromb Vasc Biol.
29:1671–1677. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lawton JS: Sex and gender differences in
coronary artery disease. Semin Thorac Cardiovasc Surg. 23:126–130.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sbarouni E, Georgiadou P and Voudris V:
Gender-specific differences in biomarkers responses to acute
coronary syndromes and revascularization procedures. Biomarkers.
16:457–465. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu G, Jousilahti P, Qiao Q, Peltonen M,
Katoh S and Tuomilehto J: The gender-specific impact of diabetes
and myocardial infarction at baseline and during follow-up on
mortality from all causes and coronary heart disease. J Am Coll
Cardiol. 45:1413–1418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Post WS, Goldschmidt-Clermont PJ, Wilhide
CC, Heldman AW, Sussman MS, Ouyang P, Milliken EE and Issa JP:
Methylation of the estrogen receptor gene is associated with aging
and atherosclerosis in the cardiovascular system. Cardiovasc Res.
43:985–991. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barrett-Connor E and Bush TL: Estrogen and
coronary heart disease in women. JAMA. 265:1861–1867. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kannel WB, Hjortland MC, McNamara PM and
Gordon T: Menopause and risk of cardiovascular disease: The
Framingham study. Ann Intern Med. 85:447–452. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hall E, Volkov P, Dayeh T, Esguerra JL,
Salö S, Eliasson L, Rönn T, Bacos K and Ling C: Sex differences in
the genome-wide DNA methylation pattern and impact on gene
expression, microRNA levels and insulin secretion in human
pancreatic islets. Genome Biol. 15:5222014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kadoglou NP, Kottas G, Lampropoulos S,
Vitta I and Liapis CD: Serum levels of fetuin-A, osteoprotegerin
and osteopontin in patients with coronary artery disease: Effects
of statin (HMGCoA-reductase inhibitor) therapy. Clin Drug Invest.
34:165–171. 2014. View Article : Google Scholar
|
|
29
|
Cross HR: Trimetazidine for stable angina
pectoris. Exp Opin Pharmacother. 2:857–875. 2001. View Article : Google Scholar
|
|
30
|
Ni W, Zhou Z, Liu T, Wang H, Deng J, Liu X
and Xing G: Gender-and lesion number-dependent difference in
‘atherogenic index of plasma’ in Chinese people with coronary heart
disease. Sci Rep. 7:132072017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou J, Huang Y, Huang RS, Wang F, Xu L,
Le Y, Yang X, Xu W, Huang X, Lian J and Duan S: A case-control
study provides evidence of association for a common SNP rs974819 in
PDGFD to coronary heart disease and suggests a sex-dependent
effect. Thromb Res. 130:602–606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tu Q, Hao J, Zhou X, Yan L, Dai H, Sun B,
Yang D, An S, Lv L, Jiao B, et al: CDKN2B deletion is essential for
pancreatic cancer development instead of unmeaningful co-deletion
due to juxtaposition to CDKN2A. Oncogene. 37:128–138. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Y, Chen M, Liu J, Li L, Yang X, Zhao J,
Wu M and Ye M: Upregulation of MicroRNA 18b contributes to the
development of colorectal cancer by inhibiting CDKN2B. Mol Cell
Biol. 37:2017. View Article : Google Scholar
|
|
34
|
Stepanenko AA and Dmitrenko VV: HEK293 in
cell biology and cancer research: Phenotype, karyotype,
tumorigenicity, and stress-induced genome-phenotype evolution.
Gene. 569:182–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Burnier JP, Borowski M, Furie BC and Furie
B: Gamma-carboxyglutamic acid. Mol Cell Biochem. 39:191–207. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Deyl Z, Macek K, Vancikova O and Adam M:
The presence of gamma-carboxyglutamic acid-containing protein in
atheromatous aortae. Biochim Biophys Acta. 581:307–315. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu YZ, Kanagaratham C, Jancik S and
Radzioch D: Promoter deletion analysis using a dual-luciferase
reporter system. Methods Mol Biol. 977:79–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kojima Y, Downing K, Kundu R, Miller C,
Dewey F, Lancero H, Raaz U, Perisic L, Hedin U, Schadt E, et al:
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and
atherosclerosis. J Clin Invest. 124:1083–1097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Svensson PA, Wahlstrand B, Olsson M,
Froguel P, Falchi M, Bergman RN, McTernan PG, Hedner T, Carlsson LM
and Jacobson P: CDKN2B expression and subcutaneous adipose tissue
expandability: Possible influence of the 9p21 atherosclerosis
locus. Biochem Biophys Res Commun. 446:1126–1131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhong J, Chen X, Ye H, Wu N, Chen X and
Duan S: CDKN2A and CDKN2B methylation in coronary heart disease
cases and controls. Exp Ther Med. 14:6093–6098. 2017.PubMed/NCBI
|
|
42
|
Vaccarino V: Ischemic heart disease in
women: Many questions, few facts. Circ Cardiovasc Qual Outcomes.
3:111–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pepine CJ, Balaban RS, Bonow RO, Diamond
GA, Johnson BD, Johnson PA, Mosca L, Nissen SE and Pohost GM:
National Heart, Lung and Blood Institute; American College of
Cardiology Foundation: Women's Ischemic Syndrome Evaluation:
Current status and future research directions: Report of the
National Heart, Lung and Blood Institute workshop: October 2-4,
2002: Section 1: Diagnosis of stable ischemia and ischemic heart
disease. Circulation. 109:e44–e46. 2004.PubMed/NCBI
|
|
44
|
Takasugi M, Hayakawa K, Arai D and Shiota
K: Age- and sex-dependent DNA hypomethylation controlled by growth
hormone in mouse liver. Mech Ageing Dev. 134:331–337. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kwekel JC, Desai VG, Moland CL, Branham WS
and Fuscoe JC: Age and sex dependent changes in liver gene
expression during the life cycle of the rat. BMC Genomics.
11:6752010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jousilahti P, Vartiainen E, Tuomilehto J
and Puska P: Sex, age, cardiovascular risk factors, and coronary
heart disease: A prospective follow-up study of 14 786 middle-aged
men and women in Finland. Circulation. 99:1165–1172. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jousilahti P, Vartiainen E, Tuomilehto J
and Puska P: Twenty-year dynamics of serum cholesterol levels in
the middle-aged population of eastern Finland. Ann Intern Med.
125:713–722. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mendelsohn ME and Karas RH: Molecular and
cellular basis of cardiovascular gender differences. Science.
308:1583–1587. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bredfeldt TG, Greathouse KL, Safe SH, Hung
MC, Bedford MT and Walker CL: Xenoestrogen-induced regulation of
EZH2 and histone methylation via estrogen receptor signaling to
PI3K/AKT. Mol Endocrinol. 24:993–1006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kulig E, Landefeld TD and Lloyd RV: The
effects of estrogen on prolactin gene methylation in normal and
neoplastic rat pituitary tissues. Am J Pathol. 140:207–214.
1992.PubMed/NCBI
|
|
51
|
Wiggins BS, Saseen JJ, Page RL II, Reed
BN, Sneed K, Kostis JB, Lanfear D, Virani S and Morris PB: American
Heart Association Clinical Pharmacology Committee of the Council on
Clinical Cardiology; Council on Hypertension; Council on Quality of
Care and Outcomes Research; and Council on Functional Genomics and
Translational Biology: Recommendations for management of clinically
significant drug-drug interactions with statins and select agents
used in patients with cardiovascular disease: A scientific
statement from the American Heart Association. Circulation.
134:e468–e495. 2016.PubMed/NCBI
|
|
52
|
Frishman WH: β-Adrenergic blockade in
cardiovascular disease. J Cardiovasc Pharmacol Ther. 18:310–319.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Horinaka S: Use of nicorandil in
cardiovascular disease and its optimization. Drugs. 71:1105–1119.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ujhelyi MR, Ferguson RK and Vlasses PH:
Angiotensin-converting enzyme inhibitors: Mechanistic
controversies. Pharmacotherapy. 9:351–362. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu MZ, He FZ and Zhang W: Epigenetic
research progress of anti-tumor drugs. Yao Xue Xue Bao.
48:1629–1636. 2013.(In Chinese). PubMed/NCBI
|
|
56
|
Stone A, Valdés-Mora F, Gee JM, Farrow L,
McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL,
Musgrove EA and Nicholson RI: Tamoxifen-induced epigenetic
silencing of oestrogen-regulated genes in anti-hormone resistant
breast cancer. PLoS One. 7:e404662012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Baker EK, Johnstone RW, Zalcberg JR and
El-Osta A: Epigenetic changes to the MDR1 locus in response to
chemotherapeutic drugs. Oncogene. 24:8061–8075. 2005. View Article : Google Scholar : PubMed/NCBI
|
